Search hospitals > Ontario > TORONTO
Novartis Investigative Site
Claim this profileTORONTO, Ontario M5G 2M9
Global Leader in Breast Cancer
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Lung Cancer
Conducts research for Myeloid Leukemia
Conducts research for Non-Small Cell Lung Cancer
222 reported clinical trials
0 medical researchers
Summary
Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lung Cancer, Myeloid Leukemia, Non-Small Cell Lung Cancer and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 235 conditions. There are 0 research doctors associated with this hospital, such as .Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderBCR-ABL1 positive
BCR-ABL positive
BCR-ABL1 e13a2 positive
Top PIs
Clinical Trials running at Novartis Investigative Site
Breast Cancer
Prostate Cancer
Lupus
Squamous Cell Carcinoma
Skin Cancer
Lymphoma
Follicular Lymphoma
Acute Lymphoblastic Leukemia
Mesothelioma
Non-Small Cell Lung Cancer
[177Lu]Lu-NeoB + Capecitabine
for Metastatic Breast Cancer
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \[177Lu\]Lu-NeoB in combination with capecitabine (dose optimization).
Recruiting1 award Phase 1 & 25 criteria
ECI830 + Ribociclib + Fulvestrant
for Breast Cancer
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Recruiting1 award Phase 1 & 25 criteria
KFA115 + Tislelizumab
for Advanced Cancers
This trial tests a new drug, KFA115, alone and with pembrolizumab in patients with advanced cancers. It aims to find the safest dose and see if the drugs can reduce tumors. The focus is on patients whose cancers are hard to treat with current options.
Recruiting1 award Phase 18 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in TORONTO, Ontario. This center is recognized for care of Breast Cancer, T-Lymphoblastic Leukemia/Lymphoma, Lung Cancer, Myeloid Leukemia, Non-Small Cell Lung Cancer and other specialties. Novartis Investigative Site is involved with conducting 222 clinical trials across 235 conditions. There are 0 research doctors associated with this hospital, such as .
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.